Michael Kelly, MD
Family Medicine · Vincennes, INNPI 1811972128
Payments from drug & device makers
Across 288 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$498
- Organogenesis Inc.$371
- AstraZeneca$342
- Johnson & Johnson$312
- AbbVie$300
- Novo Nordisk$289
- plus $3K from 32 others
What the payments were for
- Food & beverage$4,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 37 | $498 |
| Organogenesis Inc. | 11 | $371 |
| AstraZeneca | 23 | $342 |
| Johnson & Johnson | 23 | $312 |
| AbbVie(2 entities) | 22 | $300 |
| Novo Nordisk | 19 | $289 |
| Lilly USA, LLC | 18 | $267 |
| Pfizer | 15 | $219 |
| Mylan Specialty L.p. | 14 | $214 |
| GSK | 12 | $211 |
| Novartis | 13 | $187 |
| Boehringer Ingelheim | 10 | $165 |
| Integra Lifesciences Corporation | 3 | $161 |
| Kowa Pharmaceuticals America, Inc. | 10 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $121 |
| Amarin Pharma, Inc. | 7 | $105 |
| Bayer | 6 | $98 |
| Merck | 7 | $97 |
| Actelion Pharmaceuticals US, Inc. | 1 | $76 |
| Exact Sciences | 5 | $70 |
| KCI USA, Inc. | 1 | $59 |
| Verona Pharma, Inc. | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $41 |
| Ardelyx, Inc. | 1 | $29 |
| Nestle Healthcare Nutrition Inc. | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| Sonex Health, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
| Medicure Pharma Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Amneal Pharmaceuticals LLC | 1 | $11 |
How this compares
$4,646 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $97,144 |
| EliquisApixaban | 97 | $85,352 |
| TrulicityDulaglutide | 57 | $80,182 |
| JardianceEmpagliflozin | 92 | $70,246 |
| MounjaroTirzepatide | 43 | $49,261 |
| XareltoRivaroxaban | 48 | $38,329 |
| FarxigaDapagliflozin Propanediol | 47 | $35,330 |
| JanumetSitagliptin Phos/Metformin Hcl | 36 | $33,318 |
| JanuviaSitagliptin Phosphate | 34 | $26,051 |
| Repatha SureclickEvolocumab | 25 | $21,996 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $19,113 |
| LinzessLinaclotide | 21 | $18,663 |
| LivaloPitavastatin Calcium | 15 | $13,161 |
| Spiriva HandihalerTiotropium Bromide | 16 | $11,879 |
| SynthroidLevothyroxine Sodium | 86 | $7,635 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $267 | $129,443100 claims |
| Novo NordiskOzempic | $289 | $97,14485 claims |
| PfizerEliquis | $219 | $85,35297 claims |
| Boehringer IngelheimJardiance | $165 | $70,24692 claims |
| MerckJanumet, Januvia | $97 | $59,36970 claims |
| Johnson & JohnsonXarelto | $312 | $38,32948 claims |
| AstraZenecaFarxiga | $342 | $35,33047 claims |
| AbbVieLinzess, Synthroid | $300 | $26,298107 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $130 | $13,16115 claims |
| GSKAnoro Ellipta | $211 | $6,33713 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $11 | $3,193408 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Vincennes
- Jane BridgesVincennes$28K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.